Clinical Review State of the Art Review

Management and prevention of exacerbations of COPD

BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5237 (Published 22 September 2014) Cite this as: BMJ 2014;349:g5237
  1. Shawn D Aaron, professor, University of Ottawa
  1. 1Ottawa Hospital Research Institute, Ottawa, ON, Canada, K1H 8L6
  1. Correspondence to: S D Aaron saaron{at}ohri.ca

Abstract

Patients with chronic obstructive pulmonary disease (COPD) are prone to acute respiratory exacerbations, which can develop suddenly or subacutely over the course of several days. Exacerbations have a detrimental effect on patients’ health status and increase the burden on the healthcare system. Initial treatment is unsuccessful in 24-27% of patients, who have a relapse or a second exacerbation within 30 days of the initial event. No obvious benefit has been seen in recent clinical trials of anti-tumour necrosis factor therapy, anti-leukotriene therapy, intensive chest physiotherapy, or early inpatient pulmonary rehabilitation for treatment of exacerbations. By contrast, clinical trials of prevention rather than acute treatment have shown promising results. Long acting β agonist (LABA) or long acting anti-muscarinic (LAMA) bronchodilators and inhaled corticosteroid-LABA combinations prevent exacerbations in patients at risk, with relative risk reductions averaging 14-27% for each of these drugs relative to placebo. Triple therapy with inhaled corticosteroid-LABA plus LAMA may provide additional benefit, although study results to date are heterogeneous and more studies are needed. Pneumonia is an important complication of treatment with inhaled corticosteroid-LABA products, and the risk of pneumonia seems to be doubled in patients with COPD who use fluticasone. The addition of azithromycin to usual COPD therapy prevents exacerbations, although it may prolong the Q-T interval and increase the risk of death from cardiovascular disease in patients prone to arrhythmia. New potential drugs—including mitogen activated protein kinase inhibitors, phosphodiesterase 3 inhibitors, and monoclonal antibodies to the interleukin 1 receptor—offer additional hope for treatments that may prevent exacerbations in the future.

Footnotes

  • Contributors: SDA was the sole author and is guarantor.

  • Competing interests: I have read and understood BMJ policy on declaration of interests and declare the following interests: I have served on advisory boards for Boerhinger-Ingelheim, Astra-Zeneca, and Novartis and have been paid about $10 000 (£6000; €7530) for these activities in the past 24 months.

  • Provenance and peer review: Commissioned; externally peer reviewed.

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe